<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7483040/table_2" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 2</label>
  <p>
   <i>LRRK2</i>-targeted treatments including LRRK2 inhibitors and antisense oligomeres under development for PD 
  </p>
 </caption>
 <thead>
  <tr>
   <th colspan="7" rowspan="1" id="0-0-g">LRRK2</th>
  </tr>
  <tr>
   <th colspan="1" rowspan="1" id="1-0-.">Compound</th>
   <th colspan="1" rowspan="1" id="1-1-.">DNL201</th>
   <th colspan="1" rowspan="1" id="1-2-.">DNL151</th>
   <th colspan="1" rowspan="1" id="1-3-.">No public data</th>
   <th colspan="1" rowspan="1" id="1-4-.">No public data</th>
   <th colspan="1" rowspan="1" id="1-5-.">No public data</th>
   <th colspan="1" rowspan="1" id="1-6-.">BIIB094</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>Sponsor</td>
   <td>Denali</td>
   <td>Denali</td>
   <td>GSK</td>
   <td>Pfizer</td>
   <td>Genetech</td>
   <td>Biogen</td>
  </tr>
  <tr>
   <td>RCT no.</td>
   <td>NCT03710707</td>
   <td>NCT04056689</td>
   <td/>
   <td/>
   <td/>
   <td>NCT03976349</td>
  </tr>
  <tr>
   <td>Mechanism</td>
   <td>LRRK2 inhibition</td>
   <td>LRRK2 inhibition</td>
   <td>LRRK2 inhibition</td>
   <td>LRRK2 inhibition</td>
   <td>LRRK2 inhibition</td>
   <td>Antisense oligonucleotide (ASO)</td>
  </tr>
  <tr>
   <td>Status</td>
   <td>Completed</td>
   <td>Delayed because of COVID19</td>
   <td>Planned</td>
   <td>Under development</td>
   <td>Under development</td>
   <td>Ongoing, estimated completion end of 2022</td>
  </tr>
  <tr>
   <td>Phase</td>
   <td>Phase 1b</td>
   <td>Phase 1b</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>Phase 1</td>
  </tr>
  <tr>
   <td>Design</td>
   <td>Multicenter, randomized, placebo-controlled</td>
   <td>Multicenter</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>International, multicenter, placebo-controlled</td>
  </tr>
  <tr>
   <td>Total 
    <i>N</i> of patients 
   </td>
   <td>29</td>
   <td>34</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>62</td>
  </tr>
  <tr>
   <td>
    <i>LRRK2</i>-PD 
   </td>
   <td>√</td>
   <td>√</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>√</td>
  </tr>
  <tr>
   <td>Idiopathic PD</td>
   <td>√</td>
   <td>√</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>√</td>
  </tr>
  <tr>
   <td>Age</td>
   <td>30–75</td>
   <td/>
   <td>n/a</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>35–80</td>
  </tr>
  <tr>
   <td>Duration</td>
   <td>28 days</td>
   <td>28 days</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>n.d.</td>
  </tr>
  <tr>
   <td>Doses tested</td>
   <td>Low/high</td>
   <td>Three doses</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>n/a</td>
   <td>Single- and multiple-ascending-dose</td>
  </tr>
 </tbody>
</table>
